Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Analysis

Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a publicly traded company in the HEALTHCARE sector. It trades at $0.20, carries a market capitalization of $7.36M. This page summarizes the public market data, fundamentals, and frequently asked questions for LIMN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.20
• Market Cap: $7.36M
• EPS: $-0.25
• 52-Week High: $33.66
• 52-Week Low: $0.13

Market Sentiment

Liminatus Pharma, Inc. Class A Common Stock currently has a Neutral sentiment score of 0.02.

About Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. is a clinical-stage immuno-oncology firm based in La Palma, California, dedicated to pioneering innovative therapies for treating various cancer types. By harnessing advanced science and technology, the company focuses on addressing unmet medical needs within oncology through a robust therapeutic pipeline. With a strategic emphasis on clinical development, Liminatus is well-positioned to play a pivotal role in the evolving cancer treatment landscape, representing a comp...

GNG Research Analysis

GNG Research scores Liminatus Pharma, Inc. Class A Common Stock (LIMN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for LIMN.

Frequently Asked Questions

Does LIMN pay dividends?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) does not currently pay a regular dividend.

What is LIMN's market cap?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a market capitalization of $7.36M with a current stock price of $0.20.